首页> 美国卫生研究院文献>The Cochrane Database of Systematic Reviews >Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
【2h】

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation

机译:不同剂量的预防性血小板输注预防骨髓抑制性化疗或干细胞移植后血液病患者的出血

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPlatelet transfusions are used in modern clinical practice to prevent and treat bleeding in people who are thrombocytopenic due to bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding.This is an update of a Cochrane review first published in 2004, and updated in 2012 that addressed four separate questions: prophylactic versus therapeutic-only platelet transfusion policy; prophylactic platelet transfusion threshold; prophylactic platelet transfusion dose; and platelet transfusions compared to alternative treatments. This review has now been split into four smaller reviews; this review compares different platelet transfusion doses.
机译:背景技术血小板输注被用于现代临床实践中,以预防和治疗因骨髓衰竭导致血小板减少的人的出血。尽管在过去40年中血小板输注治疗取得了长足进展,但仍有一些领域引起争议,特别是在使用预防性血小板输注预防血小板减少性出血方面。这是2004年首次发表的Cochrane综述的更新内容。 ,并在2012年进行了更新,以解决四个单独的问题:预防性血小板治疗和仅治疗性血小板输注政策;预防性血小板输注阈值;预防性血小板输注剂量;和替代疗法的血小板输注。现在,该评论分为四个较小的评论;该评价比较了不同的血小板输注剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号